TAF6L

TAF6L is a non-enzymatic subunit of the SAGA transcriptional co-activator complex that links chromatin acetylation to the activation of pluripotency gene networks (PMID:31005419, PMID:42009663). As part of the SAGA CORE module, TAF6L is required for the structural integrity of the complex and for the stability of the catalytic histone acetyltransferase subunit KAT2A; loss of TAF6L disrupts SAGA assembly and shunts non-chromatin-bound KAT2A to proteasomal degradation via the E3 ligase UBR5, reducing H3K9 acetylation (PMID:42009663). Through this acetyltransferase-supporting role, TAF6L drives H3K9ac deposition and the transcriptional activation of the c-Myc and Oct4 regulatory networks that maintain embryonic stem cell self-renewal (PMID:31005419). Structurally, the TAF6L HEAT repeat domain diverges from its canonical paralog TAF6 to provide a docking surface for the metazoan splicing-factor module (SPL) within SAGA, engaging SPL through a comparatively small interface (PMID:41849588). TAF6L also functions in recovery from cisplatin-induced cytotoxicity in gastric organoids, placing it within a DNA damage response/recovery context (PMID:40813572).

1. 2019 Medium

   Established that TAF6L is functionally required for stem cell self-renewal and acts by driving acetylation-coupled transcription of the core pluripotency network, defining its biological role beyond being a structural complex subunit.

   Evidence CRISPR-Cas9 loss-of-function screen with ChIP and transcriptional analysis in mouse ESCs

   PMID:31005419

   Open questions at the time

   • Does not resolve whether the transcriptional effect is direct via SAGA at target promoters or indirect through c-MYC
   • Mechanism linking TAF6L to H3K9ac deposition not structurally defined
   • Restricted to mouse ESC context
2. 2026 High

   Defined the molecular basis by which TAF6L sustains SAGA enzymatic output, showing it stabilizes the catalytic subunit KAT2A and that its loss triggers UBR5-mediated proteasomal turnover of unincorporated KAT2A.

   Evidence KAT2A stability reporter, CRISPR perturbation of SAGA CORE subunits, proteomics, and a focused ubiquitin-proteasome CRISPR screen

   PMID:42009663

   Open questions at the time

   • Does not establish whether UBR5 directly ubiquitinates KAT2A or acts through an intermediary
   • Quantitative contribution of TAF6L loss to global vs. locus-specific H3K9ac not delineated
3. 2026 High

   Resolved how TAF6L structurally distinguishes SAGA from canonical TFIID-associated assemblies, showing its HEAT repeat domain creates a docking surface for the splicing-factor module absent in the paralog TAF6.

   Evidence High-resolution cryo-EM of affinity-purified endogenous human SAGA (peer-reviewed; corroborated by an earlier preprint, idx 4)

   PMID:41849588

   Open questions at the time

   • Functional consequence of SPL docking for splicing output not demonstrated
   • The weaker SPL-SAGA interface implies a hand-off model that is not experimentally tested
4. 2025 Medium

   Extended TAF6L function into a stress-response context by identifying it as a regulator of recovery from cisplatin cytotoxicity in human gastric tissue.

   Evidence CRISPR knockout/CRISPRi/CRISPRa screens with single-cell transcriptomics in primary human 3D gastric organoids

   PMID:40813572

   Open questions at the time

   • Mechanistic detail limited to phenotypic recovery; no molecular link to SAGA activity demonstrated in this context
   • Single study in one tissue model

• How TAF6L-dependent SPL docking is coupled to active splicing, and whether its DNA damage recovery role operates through SAGA-mediated transcription, remain unresolved.
• No functional demonstration that SPL recruitment via TAF6L alters splicing outcomes
• No mechanistic connection between TAF6L's transcriptional/acetylation role and cisplatin recovery
• Direct enzymology of UBR5-KAT2A relationship unestablished